Loring Wolcott & Coolidge Fiduciary Advisors’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Loring Wolcott & Coolidge Fiduciary Advisors’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-140	Closed	-$8K	–	741
2018 Q3	$8K	Hold	140	–	–	﹤0.01%	548
2018 Q2	$10K	Sell	140 -40	-22%	-$2.82K	﹤0.01%	550
2018 Q1	$11K	Hold	180	–	–	﹤0.01%	581
2017 Q4	$23K	Hold	180	–	–	﹤0.01%	509
2017 Q3	$25K	Hold	180	–	–	﹤0.01%	486
2017 Q2	$24K	Hold	180	–	–	﹤0.01%	479
2017 Q1	$33K	Hold	180	–	–	﹤0.01%	451
2016 Q4	$15K	Sell	180 -10	-5%	-$791	﹤0.01%	496
2016 Q3	$15K	Hold	190	–	–	﹤0.01%	512
2016 Q2	$16K	Buy	190 +50	+36%	+$4.58K	﹤0.01%	505
2016 Q1	$13K	Hold	140	–	–	﹤0.01%	519
2015 Q4	$28K	Hold	140	–	–	﹤0.01%	485
2015 Q3	$133K	Hold	140	–	–	﹤0.01%	324
2015 Q2	$133K	Hold	140	–	–	﹤0.01%	324
2015 Q1	$103K	Hold	140	–	–	﹤0.01%	363
2014 Q4	$111K	Hold	140	–	–	﹤0.01%	346
2014 Q3	$56K	Hold	140	–	–	﹤0.01%	401
2014 Q2	$38K	Hold	140	–	–	﹤0.01%	464
2014 Q1	$30K	Buy	140 +100	+250%	+$27.9K	﹤0.01%	457
2013 Q4	$11K	Buy	+40	New	+$9.54K	﹤0.01%	521

Other funds holding TTPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Loring Wolcott & Coolidge Fiduciary Advisors's TTPH Position: Q4 2018 in Review

Loring Wolcott & Coolidge Fiduciary Advisors sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q4 2018, closing a stake of 140 shares — an estimated $8K sold.

Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in TTPH in Q4 2013 and held it in 20 quarters. The position peaked at $133K in Q3 2015. 86 funds tracked by Wall St. Rank hold TTPH as of Q4 2018.

Loring Wolcott & Coolidge Fiduciary Advisors reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Loring Wolcott & Coolidge Fiduciary Advisors sold 140 Tetraphase Pharmaceuticals, Inc. shares in Q4 2018, an estimated $8K.
Loring Wolcott & Coolidge Fiduciary Advisors first reported a position in Tetraphase Pharmaceuticals, Inc. in Q4 2013 and held it in 20 quarters.
Loring Wolcott & Coolidge Fiduciary Advisors's Tetraphase Pharmaceuticals, Inc. position peaked at $133K in Q3 2015.
86 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q4 2018.

Based on Loring Wolcott & Coolidge Fiduciary Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.